. Original data used for Figure 1A Figure S1. BRAF and MEK inhibitor treatment affects CAR-T-cell activation after antigen-specific stimulation. CAR-T cells were generated as described in figure 1. Four hours after electroporation, these cells were co-incubated over-night with CSPG4-negative T2 cells and the CSPG4 + melanoma cell line A375M at a 1:1 ratio. Mock-transfected T cells were used as control. Co-incubations were performed in the absence of inhibitors (no inhibitor), in the presence of DMSO only (solvent control), or in the presence of the different kinase inhibitors, either alone or in combination. The used kinase inhibitors vemurafenib (Vem, V), dabrafenib (Dabra, D), cobimetinib (Cobi, C), and trametinib (Tram, T) were used in final concentrations listed in Table 1 . Mock-transfected T cells stimulated with T2 or A375M, and mock-transfected T cells and CAR-T cells incubated without target cells served as negative controls. After 16 hours of co-incubation, the cells were harvested and stained for the activation markers CD25 (a) and CD69 (b) and measured by flow cytometry. Histograms of a representative donor are depicted. 
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1 Cytokine concentrations were determined by Cytometric Bead Arrays. See legend to figure 3 and materials and methods section for details. Table S12 . Original data used for figure 5 1 . 
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